Which new diabetes drugs pose risk of digestive diseases?
China: Glucagon-like peptide 1 receptor agonists (GLP1RAs) should not be given to patients at high risk of certain digestive diseases, whereas dipeptidyl DPP4 and SGLT2 inhibitors were safe for patients susceptible to digestive disorders, according to results from a meta-analysis published in Medicine.
The study showed that neither dipeptidyl peptidase-4 inhibitors (DPP4is) nor sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with several kinds of digestive disease. GLP1RAs were shown to be associated with a higher risk of 4 types of digestive disorders (pancreatitis, gastric ulcer hemorrhage, cholecystitis acute, and cholangitis acute).
New hypoglycemic agents for diabetes treatment are divided into three classes: GLP1R agonists such as semaglutide and liraglutide, SGLT2 inhibitors such as empagliflozin and canagliflozin, and DPP4 inhibitors such as linagliptin and sitagliptin. GLP1RAs and SGLT2is can also exert renal and cardiovascular protection effects. The relation between each class of these new hypoglycemic drugs and the risk of several digestive system diseases remains unknown. Therefore, Cui-Shan Yang, Shenzhen Longhua District Central Hospital, Shenzhen, China, and colleagues aimed to explore this relationship by conducting a meta-analysis.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.